Inventiva Announces The Recommendation Of The Fifth DMC Of The NATiV3 Phase 3 Clinical Trial With Lanifibranor In Patients With MASH
Portfolio Pulse from Benzinga Newsdesk
Inventiva's NATiV3 Phase 3 clinical trial for lanifibranor in MASH patients continues as planned, following a positive safety review by the Data Monitoring Committee.
October 30, 2024 | 8:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Inventiva's NATiV3 Phase 3 trial for lanifibranor in MASH patients continues without changes after a positive safety review by the DMC, indicating a good safety profile.
The continuation of the trial without modifications after a positive safety review suggests confidence in the drug's safety profile, which is a positive indicator for the company's prospects and could lead to a favorable market reaction.
CONFIDENCE 95
IMPORTANCE 80
RELEVANCE 90